OC
RMD icon

Oppenheimer & Co’s ResMed RMD Stock Holding History

Oppenheimer & Co’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,465
Closed -$1.08M – 1512
2024
Q1 		$1.08M Hold
5,465
– – 0.02% 716
2023
Q4 		$940K Buy
5,465
+500
+10% +$76.8K 0.02% 727
2023
Q3 		$734K Sell
4,965
-9
-0.2% -$1.63K 0.02% 786
2023
Q2 		$1.09M Buy
4,974
+9
+0.2% +$2.01K 0.02% 671
2023
Q1 		$1.09M Sell
4,965
-30
-0.6% -$6.51K 0.02% 661
2022
Q4 		$1.04M Hold
4,995
– – 0.02% 666
2022
Q3 		$1.09M Sell
4,995
-935
-16% -$213K 0.03% 626
2022
Q2 		$1.24M Buy
+5,930
New +$1.26M 0.03% 609
2021
Q1 		– Sell
-5,245
Closed -$1.11M – 1496
2020
Q4 		$1.11M Sell
5,245
-2,594
-33% -$517K 0.02% 611
2020
Q3 		$1.34M Sell
7,839
-506
-6% -$93.4K 0.03% 485
2020
Q2 		$1.6M Buy
8,345
+6,094
+271% +$997K 0.04% 426
2020
Q1 		$332K Buy
+2,251
New +$359K 0.01% 872
2015
Q1 		– Sell
-9,790
Closed -$549K – 1534
2014
Q4 		$549K Buy
+9,790
New +$511K 0.02% 786

Other funds holding RMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Oppenheimer & Co's RMD Position: Q2 2024 in Review

Oppenheimer & Co sold out of ResMed (RMD) in Q2 2024, closing a stake of 5,465 shares — an estimated $1.08M sold.

Oppenheimer & Co first reported a position in RMD in Q4 2014 and held it in 13 quarters. The position peaked at $1.6M in Q2 2020. 771 funds tracked by Wall St. Rank hold RMD as of Q2 2024.

  • Oppenheimer & Co reported no remaining ResMed position as of Q2 2024 after selling out during the quarter.
  • Oppenheimer & Co sold 5,465 ResMed shares in Q2 2024, an estimated $1.08M.
  • Oppenheimer & Co first reported a position in ResMed in Q4 2014 and held it in 13 quarters.
  • Oppenheimer & Co's ResMed position peaked at $1.6M in Q2 2020.
  • 771 funds tracked by Wall St. Rank held ResMed as of Q2 2024.

Based on Oppenheimer & Co's 13F filing for Q2 2024, filed 8 Aug 2024.